Uncategorized

Big Pharma restructures to ride out ‘existential risk’

Published

on

Even biopharma’s biggest players have been forced to take a hard look at their businesses and realign their cost structures to cope with the continued and compounding challenges plaguing the industry.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version